Food and Drug Administration (FDA) in early June and sold under the brand name Wegovy, is for chronic weight management in clinically obese adults, who are defined as those with a body mass index (BMI) of 30 or greater
Adjacent innovations shown at the event, such as water-free stick formats and melt-in-mouth, directly-dosed powders, point the same direction: reduce the volume and the effort a user has to tolerate
Stanford FC, Tauqeer Z, Kyle TK
MASLD/MASH can be caused by several factors, including a persons genetics, but both obesity and diabetes are major contributors
This transition could help in sustaining motivation and adherence to treatment over the long term. This maintenance approach is currently being investigated
The body becomes resistant to insulin and can no longer use glucose properly as a fuel, so glucose begins circulating in the bloodstream and may lead to problems with the circulatory, nervous and immune systems